Mapping MAGE-A4 expression in solid cancers for targeted therapies
Frontiers in Oncology · 13.03.2025 · 15
DOI: 10.3389/fonc.2025.1484182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 13.03.2025. Verfasst von Christin Habigt und 16 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Munich, Penzberg, Germany. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Melanoma-associated antigen A4 (MAGE-A4) is a promising target for anticancer therapy. However, limited contemporary data are available on the details of MAGE-A4 protein expression in different cancer types. In this study, the protein expression of MAGE-A4 is comprehensively studied in patients with unresectable and/or metastatic solid cancers to identify indications of the highest unmet medical need for anti-MAGE-A4 therapy. FFPE tumor sections from 200 patients, predominantly HLA-A*02:01 positive ( n = 193), were examined using immunohistochemistry (IHC) to detect MAGE-A4 expression. The patient cohort comprised various cancer types to pinpoint differences in the prevalence and intensity of MAGE-A4 positivity. MAGE-A4 expression was observed in 35% (69 patients) of the overall cohort. Certain cancer types exhibited notably higher frequencies of MAGE-A4 positivity. Specifically, adenoid cystic carcinoma demonstrated the highest prevalence at 82%, followed by liposarcoma at 67%. Ovarian serous/high-grade carcinoma showed a 64% positivity rate, identical to that observed in squamous non-small cell lung cancer (NSCLC). Head and neck squamous cell carcinoma (HNSCC) presented a 60% prevalence, while esophageal cancer had a 54% prevalence of MAGE-A4 expression. These data highlight the variability of MAGE-A4 expression across different cancer types and underscore its relevance as a potential target of novel precision medicines. The significant presence of MAGE-A4 in specific cancers suggests potential for stratified therapeutic approaches and warrants further investigation into its role in oncogenesis and treatment response.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Munich, Penzberg, Germany.
- Department of Medical Oncology, UZ Gent, Ghent, Belgium.
- Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Phase I Drug Development Unit, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.
- Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.
- START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain.
Zitieren
APA
Habigt, C., Rottey, S., Spanggaard, I., Lopez, J. S., Garralda, E., Calvo, E., Bechter, O., Desai, J., Galot, R., Gandhi, L., Heil, F., Rieder, N., Dimitrov, I., Quetglas, I. M., Heichinger, C., Keshelava, N., & Roller, A. (2025). Mapping MAGE-A4 expression in solid cancers for targeted therapies. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1484182
Vancouver
Habigt C, Rottey S, Spanggaard I, Lopez JS, Garralda E, Calvo E, et al. Mapping MAGE-A4 expression in solid cancers for targeted therapies. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1484182
BibTeX
@article{Habigt2025,
author = {Habigt, Christin and Rottey, Sylvie and Spanggaard, Iben and Lopez, Juanita S and Garralda, Elena and Calvo, Emiliano and Bechter, Oliver and Desai, Jayesh and Galot, Rachel and Gandhi, Leena and Heil, Florian and Rieder, Natascha and Dimitrov, Ivan and Quetglas, Iris Martinez and Heichinger, Christian and Keshelava, Nino and Roller, Andreas},
title = {Mapping MAGE-A4 expression in solid cancers for targeted therapies},
journal = {Frontiers in Oncology},
year = {2025},
volume = {15},
doi = {10.3389/fonc.2025.1484182}
}
EUVIMED